WILMINGTON, Del., May 16, 2016 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced today that it has extended its previously announced offer (the "Exchange Offer") to exchange any and all of its $1,350 million aggregate principal amount of 6.625% Senior Notes due 2023 (the "2023 Notes"), $750 million aggregate principal amount of 7.000% Senior Notes due 2025 (the "2025 Notes") and €360 million aggregate principal amount of 6.125% Senior Notes due 2023 which were issued in a private placement on May 12, 2015 (the "Euro Notes," and together with the 2023 Notes and the 2025 Notes, the "Original Notes") for an equal principal amount of its $1,350 million aggregate principal amount of 6.625% Senior Notes due 2023, $750 million aggregate principal amount of 7.000% Senior Notes due 2025 and €360 million aggregate principal amount of 6.125% Senior Notes due 2023, which have been registered under the Securities Act of 1933, as amended.
The Exchange Offer, which had originally been scheduled to expire at 11:59 p.m., New York City time, on May 13, 2016, will now expire at 11:59 p.m., New York City time, on May 17, 2016, subject to Chemours' right to further extend the expiration date for the Exchange Offer.
The extension of the Exchange Offer has been made to allow holders of outstanding 2023 Notes and 2025 Notes who have not yet tendered their 2023 Notes and 2025 Notes for exchange additional time to do so. The extension of the Exchange Offer will not apply to the Euro Notes. Tenders of the 2023 Notes and the 2025 Notes during this extension period will not have any withdrawal rights. All other terms of the Exchange Offer, as set forth in the prospectus dated April 13, 2016 (the "Prospectus") and the accompanying letter of transmittal, will remain in full force and effect, except that the expiration date for withdrawals of tenders of the 2023 Notes and the 2025 Notes and the deadline for complying with the guaranteed delivery procedures for the 2023 Notes and the 2025 Notes will not be extended.
Chemours has been advised that, as of 5:30 p.m. New York City time, on May 13, 2016, $1,347,778,000 in aggregate principal amount of the 2023 Notes and $747,280,000 in aggregate principal amount of the 2025 Notes had been validly tendered and not withdrawn in the Exchange Offer, representing 99.835% and 99.637% of the aggregate principal amount outstanding of the 2023 Notes and the 2025 Notes, respectively.
Requests for assistance or for copies of documents related to the exchange of outstanding Original Notes denominated in U.S. dollars, including the Prospectus and the related letter of transmittal, should be directed to the exchange agent, U.S. Bank National Association, at (800) 934-6802.
This press release is for informational purposes only and shall not constitute an offer to exchange, nor a solicitation of an offer to exchange, any securities. The Exchange Offer is being made only pursuant to the Prospectus and the accompanying letter of transmittal and only to such persons and in such jurisdictions as is permitted under applicable law.
About The Chemours Company
The Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry. Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™. Chemours has approximately 8,000 employees across 35 manufacturing sites serving more than 5,000 customers in North America, Latin America, Asia-Pacific and Europe. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC. For more information please visit chemours.com or follow Chemours on Twitter at @chemours.
This press release contains forward-looking statements, which often may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements also are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements, as further described in the registration statement on Form S-4 related to the Exchange Offer, as filed with the Securities and Exchange Commission. Chemours undertakes no duty to update any forward-looking statements.
Global Corporate Communications Leader
Director of Investor Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-chemours-company-extends-exchange-offer-for-its-6625-senior-notes-due-2023-and-7000-senior-notes-due-2025-300269126.html
SOURCE The Chemours Company